It's a question that comes up constantly — from patients wondering if the NP managing their care can write them a prescription, from nursing students considering the NP career path, and from healthcare administrators trying to understand what their NPs are authorised to do. The answer has changed significantly over the past two decades as states have progressively expanded NP scope of practice, and it continues to evolve. Getting the current answer right matters because it affects patient access to care, NP career planning, and how healthcare organisations staff their practices.
Yes — nurse practitioners can prescribe medication in all 50 U.S. states, the District of Columbia, and all U.S. territories. However, the scope of that prescriptive authority varies significantly by state. In some states, NPs have full independent prescriptive authority — they can prescribe any medication, including controlled substances, without physician oversight. In other states, NPs must have a collaborative agreement with a physician or work under physician supervision to prescribe, and their authority over controlled substances may be limited or require additional agreements.
This is one of the most commonly asked questions about nurse practitioners, and the answer matters both for NPs navigating their scope of practice and for patients who want to understand whether their NP can manage their medications independently. The short answer is yes, NPs prescribe. The longer answer involves understanding the three categories of state practice authority, what a collaborative agreement actually requires, how controlled substance prescribing works, and why these rules are evolving as the healthcare system increasingly relies on NPs to provide primary care.
As of 2026, 27 states plus the District of Columbia grant nurse practitioners full practice authority (FPA), meaning NPs can evaluate patients, diagnose conditions, order and interpret diagnostic tests, and prescribe medications — including controlled substances — without any physician involvement. The remaining states impose varying levels of restriction, from requiring a collaborative agreement with a physician (which may be a formality in practice) to requiring direct physician supervision of prescribing decisions.
The trend is clearly toward expanded NP authority. Multiple states have moved from restricted to full practice authority in recent years, driven by physician shortages in rural and underserved areas, evidence that NP-provided care produces comparable patient outcomes, and advocacy from nursing organisations. Understanding where your state falls on this spectrum — and what it means practically for prescribing — is essential for current and aspiring nurse practitioners.
Prescriptive authority begins with education. NPs must complete a Master of Science in Nursing (MSN) or Doctor of Nursing Practice (DNP) programme with a nurse practitioner specialisation. These programmes include substantial pharmacology coursework — typically 3 or more credits of advanced pharmacology — covering drug mechanisms, prescribing principles, drug interactions, and patient-specific dosing considerations. The pharmacology education is a prerequisite for prescriptive authority in every state.
After completing the graduate programme, NPs must pass a national certification exam from either the American Nurses Credentialing Center (ANCC) or the American Academy of Nurse Practitioners Certification Board (AANP). Certification validates clinical competency in the NP's specialty area — Family NP, Adult-Gerontology NP, Psychiatric-Mental Health NP, Pediatric NP, or others. National certification is required for state licensure and, by extension, for prescriptive authority.
Each state's board of nursing (or equivalent regulatory body) issues NP licenses that include prescriptive authority — either automatically as part of the NP licence or through a separate prescriptive authority application. In reduced practice states, the application may require documentation of a collaborative agreement with a physician. The specific requirements (application forms, fees, documentation) vary by state. Processing times range from a few weeks to several months.
To prescribe controlled substances (Schedules II–V), NPs must register with the Drug Enforcement Administration (DEA) and obtain a DEA number. The DEA registration is separate from state licensure and applies regardless of whether the NP is in a full practice or reduced practice state. DEA registration requires a state licence with prescriptive authority as a prerequisite. The registration costs approximately $888 for a 3-year period and must be renewed before expiration.
In reduced practice states, NPs must establish a formal collaborative agreement with a licensed physician before they can prescribe. The agreement specifies the scope of the NP's prescriptive authority, any limitations on controlled substance prescribing, consultation requirements, and the process for physician review. In full practice authority states, no collaborative agreement is required — the NP practises independently. Some states require collaborative agreements only for an initial transition period (often 2–5 years) after which the NP can practise independently.
The most important distinction in NP prescriptive authority is whether your state grants full practice authority (FPA) or requires some form of physician involvement. This distinction affects not just prescribing but the NP's entire scope of practice — including the ability to evaluate patients, diagnose, order tests, and treat independently.
In full practice authority states, NPs function as independent practitioners. They can open their own practices, see patients without physician referral, prescribe any medication within their scope (including controlled substances), and manage patient care from initial evaluation through ongoing treatment without any physician agreement, supervision, or oversight. FPA states include Arizona, Colorado, Connecticut, Hawaii, Idaho, Iowa, Maine, Maryland, Minnesota, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oregon, Rhode Island, South Dakota, Vermont, Washington, Wyoming, and several others that have transitioned in recent years.
In reduced practice states, NPs must maintain a collaborative or supervisory relationship with a physician to prescribe. The practical requirements of this relationship vary enormously. In some states, the collaborating physician must review a percentage of the NP's charts regularly. In others, the physician simply needs to be available for consultation — which may mean a phone call a few times a month. In a few states, the physician must physically co-sign certain prescriptions. The collaborative agreement is often a formality rather than an active supervisory relationship, but it creates an administrative burden and dependency that limits NP autonomy.
Transition states occupy a middle ground — they grant NPs full practice authority after completing a supervised transition period. In these states, newly licensed NPs must practise under a collaborative agreement for a specified number of years (typically 2–5) or supervised clinical hours (often 2,000–4,000), after which they can apply for full independent practice.
This model addresses concerns about newly graduated NP readiness while still providing a pathway to full independence. For NPs in transition states, keeping meticulous documentation of supervised hours and meeting all transition requirements on schedule is essential — delays in completing the transition period extend the time you spend under collaborative agreement restrictions and the associated administrative overhead.
From a practical standpoint, the differences between FPA and reduced practice states matter most for NPs considering opening their own practice or working in rural settings. In FPA states, an NP can establish an independent primary care clinic without needing any physician relationship — a significant advantage in areas where physicians are scarce and finding a collaborator would be difficult or expensive.
NPs can prescribe all non-controlled medications in every state — antibiotics, blood pressure medications, diabetes drugs, antidepressants (non-controlled), cholesterol medications, inhalers, and any other prescription drug that is not a DEA-scheduled controlled substance. This authority is included in the NP's standard prescriptive authority and does not require DEA registration. The vast majority of medications NPs prescribe fall into this category.
NPs can prescribe Schedule III (e.g. testosterone, some combination opioids like Tylenol with codeine), Schedule IV (e.g. benzodiazepines like Xanax and Valium, sleep medications like Ambien), and Schedule V (e.g. low-dose codeine cough syrup, pregabalin) controlled substances in virtually all states. DEA registration is required. Some reduced practice states limit the quantity or duration of controlled substance prescriptions, or require the collaborating physician's review for these prescriptions.
Schedule II drugs — opioids like oxycodone and hydrocodone, stimulants like Adderall and Ritalin, and others — represent the most restricted prescribing category. Most states allow NPs to prescribe Schedule II substances, but some impose additional requirements: shorter prescription durations, mandatory prescription drug monitoring programme (PDMP) checks, limits on refills, or specific collaborative agreement provisions for Schedule II prescribing. A small number of states restrict NPs from prescribing Schedule II substances altogether.
Schedule I substances (e.g. heroin, LSD, psilocybin — drugs with no accepted medical use under federal law) cannot be prescribed by any practitioner, including physicians. Beyond this, NPs are limited by their scope of practice and specialty certification — a Family NP shouldn't prescribe complex oncology regimens outside their training, just as a paediatrician wouldn't prescribe geriatric medications. NPs are expected to prescribe within their competency and refer when a patient's needs exceed their expertise.
Yes — a prescription written by a nurse practitioner is legally identical to one written by a physician. Pharmacies fill NP prescriptions using the NP's own prescriber number (NPI) and DEA number (for controlled substances).
For most primary care needs, yes. NPs are trained to provide comprehensive primary care including diagnosis, treatment, and ongoing medication management.
To prescribe any controlled substance (Schedules II–V), nurse practitioners must obtain their own DEA registration number — a unique identifier that authorises them to prescribe, administer, and dispense controlled substances. The DEA number is separate from the NP's state licence and separate from any collaborating physician's DEA number. NPs apply directly to the DEA after obtaining state prescriptive authority that includes controlled substances.
The DEA registration process involves submitting an application through the DEA's online system, paying a registration fee (approximately $888 for a 3-year registration as of 2025–2026), and waiting for approval (typically 4–6 weeks). The registration is tied to a specific address — NPs who practise at multiple locations may need to register each location separately, depending on DEA rules and the specific practice arrangement.
Prescription Drug Monitoring Programme (PDMP) requirements apply to NPs just as they do to physicians. Most states require prescribers to check the state PDMP before prescribing controlled substances — particularly opioids and benzodiazepines — to identify patients who may be receiving controlled substances from multiple providers. PDMP checks are a legal requirement in most states and a clinical best practice everywhere. NPs access the PDMP using their own prescriber credentials and are responsible for reviewing the results before prescribing.
Nurse practitioners who prescribe buprenorphine for opioid use disorder have additional considerations. Federal regulations that previously required a special waiver (DATA 2000 X-waiver) to prescribe buprenorphine were eliminated in 2023, allowing any practitioner with a DEA number and valid prescriptive authority to prescribe buprenorphine. NPs can now prescribe buprenorphine for opioid addiction treatment without any additional waiver or certification — a significant expansion of access to medication-assisted treatment, particularly in underserved areas where NPs are often the primary prescribers.
In a typical primary care setting, an NP's prescribing looks virtually identical to a physician's. The NP evaluates the patient, takes a history, performs a physical examination, orders diagnostic tests if needed, arrives at a diagnosis, and prescribes appropriate medication. They consider the patient's allergies, current medications, kidney and liver function, pregnancy status, and insurance formulary when selecting a medication and dosage.
The most commonly prescribed medication categories for NPs in primary care include antibiotics (for infections), antihypertensives (for blood pressure management), statins (for cholesterol), antidiabetic medications (for blood sugar control), antidepressants (SSRIs and SNRIs), proton pump inhibitors (for acid reflux), thyroid medications, and contraceptives. For acute visits, NPs frequently prescribe short courses of antibiotics, anti-inflammatories, antivirals, and symptom management medications.
Controlled substance prescribing is a smaller but important part of NP practice. NPs prescribe Schedule II medications like stimulants for ADHD, short-term opioid prescriptions for acute pain (post-surgical, post-injury), and occasionally long-term controlled substances for chronic conditions under established treatment protocols. Psychiatric-Mental Health NPs prescribe controlled substances more frequently — including benzodiazepines for anxiety disorders and stimulants for ADHD — as a core part of their psychiatric medication management role.
Medication management goes beyond writing prescriptions. NPs also conduct medication reconciliation at every patient visit — reviewing all medications the patient is taking (including over-the-counter drugs and supplements), identifying potential interactions, adjusting dosages based on lab results and clinical response, and discontinuing medications that are no longer appropriate. This comprehensive approach to medication management is a core NP competency that ensures prescribing safety across the patient's entire medication regimen, not just the medication being prescribed at a given visit.
Electronic prescribing (e-prescribing) has become the standard for NP prescribing, just as it has for physicians. NPs use electronic health record (EHR) systems to send prescriptions directly to pharmacies, check drug interactions automatically, verify insurance formulary coverage, and maintain a comprehensive medication record for each patient. For controlled substances, the Electronic Prescribing for Controlled Substances (EPCS) system adds additional security (two-factor authentication) to prevent fraud and ensure prescription integrity.
The trajectory of NP prescriptive authority in the United States is toward broader independence. Several states have moved from restricted to full practice authority in recent years, and multiple others have active legislative efforts to do the same. The COVID-19 pandemic accelerated this trend — many states issued emergency orders expanding NP scope of practice during the pandemic, and some have made those expansions permanent based on positive outcomes.
Telehealth has added a new dimension to NP prescribing. NPs increasingly provide care across state lines via telehealth platforms, which raises questions about which state's prescriptive authority rules apply — the NP's home state or the patient's location. The Nurse Licensure Compact (NLC) allows RN licence portability across member states, but NP-specific compacts for advanced practice are still developing. For telehealth prescribing, NPs generally must hold licensure in the state where the patient is located, which means understanding multiple states' prescriptive authority rules.
Federal legislation could eventually standardise NP practice authority nationwide, eliminating the state-by-state patchwork that currently exists. The Full Practice Authority for Nurse Practitioners Act and similar federal proposals would establish uniform FPA for NPs across all states. While these bills haven't passed as of 2026, they reflect growing recognition that state-level variation in NP authority creates unnecessary barriers to care — particularly in states with the most severe physician shortages, which often have the most restrictive NP scope-of-practice laws.
For NP students currently in graduate programmes, the expanding scope of practice is encouraging for career prospects. As more states adopt FPA and as the healthcare system continues grappling with physician shortages, the demand for NPs with prescriptive authority will only increase. Understanding the prescriptive authority landscape — and planning your career with state-specific rules in mind — positions you to take advantage of these opportunities as they develop.
If you have a choice of where to practise, FPA states offer the broadest scope and the fewest administrative barriers to building an independent practice. The states that moved to FPA most recently may also have the most favourable practice environments, since they've adopted modern regulatory frameworks without the legacy restrictions that older and more complex regulatory structures sometimes carry forward unnecessarily.
In reduced practice states, the collaborative agreement between an NP and a physician is the legal document that authorises the NP's prescriptive authority. Understanding what these agreements require — and don't require — is important for NPs working in these states.
A typical collaborative agreement specifies the NP's scope of prescriptive authority (which medications and schedules the NP can prescribe), the conditions under which the NP should consult the collaborating physician, the physician's oversight responsibilities (how often charts are reviewed, what percentage of prescriptions are audited), and the process for handling clinical situations that exceed the NP's agreed scope. The agreement is a legal document filed with the state board of nursing.
In practice, many collaborative agreements function as paper requirements rather than active supervisory relationships. The collaborating physician may review a small percentage of charts quarterly, be available by phone for questions, and renew the agreement annually — without any day-to-day involvement in the NP's prescribing decisions. This is particularly common in primary care settings where the NP manages a panel of patients independently and consults the physician only for genuinely complex cases.
Finding a collaborating physician can be challenging for NPs, particularly in rural areas. Some physicians charge a fee for collaborative agreements ($500–$2,000+ per month), which adds an overhead cost that NPs in full practice states don't incur. In areas with physician shortages, finding a willing collaborator at all can delay an NP's ability to start prescribing. This practical barrier is one of the strongest arguments for expanding FPA — the physician shortage that creates the need for NP prescribers simultaneously makes it harder for NPs to meet the collaboration requirement.
If you're an NP seeking a collaborating physician, start by reaching out to physicians you've worked with clinically — an existing professional relationship makes the conversation easier. State NP associations often maintain lists of physicians willing to enter collaborative agreements, and some states have online matching services. Before signing an agreement, clarify the physician's expectations regarding chart review frequency, consultation availability, and any fees they charge. Get the terms in writing and ensure both parties understand the scope of the agreement before filing it with the board of nursing.